Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IGHID 12107 - A Phase I Study to Evaluate the Safety and Immunogenicity of the ChAdOx1.HIVconsv62 - MVA.tHIVconsv4 (C62-M4) or, ChAdOx1.tHIVconsv1+C62 - MVA.tHIVconsv3+M4 (C1C62-M3M4) Prime-Boost Regimens in Persons With HIV-1 Suppressed on Antiretroviral Therapy

NCT05604209 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.

NCT NCT05604209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05604209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IGHID 12107 - A Phase I Study to Evaluate the Safety and Immunogenicity of the ChAdOx1.HIVconsv62 - MVA.tHIVconsv4 (C62-M4) or, ChAdOx1.tHIVconsv1+C62 - MVA.tHIVconsv3+M4 (C1C62-M3M4) Prime-Boost Regimens in Persons With HIV-1 Suppressed on Antiretroviral Therapy
Lead sponsor
University of North Carolina, Chapel Hill
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2022
Completion date
January 10, 2025
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv vaccine, hiv-1-infection